263 related articles for article (PubMed ID: 21317715)
1. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.
Miettinen M; Wang ZF; Paetau A; Tan SH; Dobi A; Srivastava S; Sesterhenn I
Am J Surg Pathol; 2011 Mar; 35(3):432-41. PubMed ID: 21317715
[TBL] [Abstract][Full Text] [Related]
2. ERG expression in epithelioid sarcoma: a diagnostic pitfall.
Miettinen M; Wang Z; Sarlomo-Rikala M; Abdullaev Z; Pack SD; Fetsch JF
Am J Surg Pathol; 2013 Oct; 37(10):1580-5. PubMed ID: 23774169
[TBL] [Abstract][Full Text] [Related]
3. Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors.
Miettinen M; Wang ZF
Am J Surg Pathol; 2012 Mar; 36(3):351-9. PubMed ID: 22067331
[TBL] [Abstract][Full Text] [Related]
4. ERG protein expression in human tumors detected with a rabbit monoclonal antibody.
Yaskiv O; Rubin BP; He H; Falzarano S; Magi-Galluzzi C; Zhou M
Am J Clin Pathol; 2012 Dec; 138(6):803-10. PubMed ID: 23161713
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.
Miettinen M; Rikala MS; Rys J; Lasota J; Wang ZF
Am J Surg Pathol; 2012 Apr; 36(4):629-39. PubMed ID: 22314185
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Vascular Markers (Immunohistochemical Stains) in Soft Tissue Sarcomas.
Naeem N; Mushtaq S; Akhter N; Hussain M; Hassan U
J Coll Physicians Surg Pak; 2018 May; 28(5):352-356. PubMed ID: 29690962
[TBL] [Abstract][Full Text] [Related]
7. ERG and FLI1 protein expression in epithelioid sarcoma.
Stockman DL; Hornick JL; Deavers MT; Lev DC; Lazar AJ; Wang WL
Mod Pathol; 2014 Apr; 27(4):496-501. PubMed ID: 24072183
[TBL] [Abstract][Full Text] [Related]
8. High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers.
Minner S; Luebke AM; Kluth M; Bokemeyer C; Jänicke F; Izbicki J; Schlomm T; Sauter G; Wilczak W
Histopathology; 2012 Sep; 61(3):445-53. PubMed ID: 22463702
[TBL] [Abstract][Full Text] [Related]
9. ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma.
Schneider TM; Osunkoya AO
Mod Pathol; 2014 Aug; 27(8):1174-8. PubMed ID: 24406865
[TBL] [Abstract][Full Text] [Related]
10. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Yamada Y; Hotokebuchi Y; Yamamoto H; Taguchi T; Iwamoto Y; Oda Y
Hum Pathol; 2015 Feb; 46(2):225-30. PubMed ID: 25479928
[TBL] [Abstract][Full Text] [Related]
11. Claudin-5 as an immunohistochemical marker for angiosarcoma and hemangioendotheliomas.
Miettinen M; Sarlomo-Rikala M; Wang ZF
Am J Surg Pathol; 2011 Dec; 35(12):1848-56. PubMed ID: 21959309
[TBL] [Abstract][Full Text] [Related]
12. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody.
Rossi S; Orvieto E; Furlanetto A; Laurino L; Ninfo V; Dei Tos AP
Mod Pathol; 2004 May; 17(5):547-52. PubMed ID: 15001993
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.
Tomlins SA; Palanisamy N; Brenner JC; Stall JN; Siddiqui J; Thomas DG; Lucas DR; Chinnaiyan AM; Kunju LP
Am J Clin Pathol; 2013 Jun; 139(6):771-9. PubMed ID: 23690120
[TBL] [Abstract][Full Text] [Related]
14. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
15. ERG is a novel and reliable marker for endothelial cells in central nervous system tumors.
Haber MA; Iranmahboob A; Thomas C; Liu M; Najjar A; Zagzag D
Clin Neuropathol; 2015; 34(3):117-27. PubMed ID: 25881913
[TBL] [Abstract][Full Text] [Related]
16. ERG positive prostatic cancer may show a more angiogenetic phenotype.
Strzępek A; Kaczmarczyk K; Białas M; Szpor J; Dyduch G; Szopiński T; Chłosta P; Okoń K
Pathol Res Pract; 2014 Dec; 210(12):897-900. PubMed ID: 25220615
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
18. Keratin 1 expression in endothelia and mesenchymal tumors: an immunohistochemical analysis of normal and neoplastic tissues.
Remotti F; Fetsch JF; Miettinen M
Hum Pathol; 2001 Aug; 32(8):873-9. PubMed ID: 11521233
[TBL] [Abstract][Full Text] [Related]
19. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
Warrick JI; Humphrey PA
Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
[TBL] [Abstract][Full Text] [Related]
20. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics.
Folpe AL; Chand EM; Goldblum JR; Weiss SW
Am J Surg Pathol; 2001 Aug; 25(8):1061-6. PubMed ID: 11474291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
